title: B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element.
abstract: Retroviral gene transfer resulting in transgene expression selectively restricted to specific cell lineages would be desirable for many gene therapeutic applications. Such transcriptional targeting of retroviruses can be accomplished by employing eukaryotic control elements in self-inactivating (SIN) retroviral vectors, but use of these vectors is complicated by an accompanying reduction in viral titers. To overcome this restriction and address the influence of the post-transcriptional regulatory element of the Woodchuck hepatitis virus (WPRE) on viral titers and transgene expression, we developed SIN-vectors with and without WPRE. Using the enhancer-promoter of the Spleen Focus Forming virus (SFFV) to direct eGFP expression to multiple hematopoietic lineages, we show that WPRE significantly (>10 x) increased viral titers (>10(6) per ml of unconcentrated supernatant) and transgene expression in NIH3T3 cells in vitro. Gene expression in vivo was significantly lowered in lymphoid cells, but not in myeloid cells when WPRE was present. Furthermore, the use of WPRE in combination with the B-cell lineage-specific CD19 promoter significantly increased viral titers and allowed targeting of transgene expression by SIN-vectors specifically to B cells throughout their development in primary and secondary lymphoid organs.
authors.affiliation: Institute for Immunology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Werner
authors.forename: J
authors.initials: J
authors.lastname: Kraunus
authors.forename: C
authors.initials: C
authors.lastname: Baum
authors.forename: T
authors.initials: T
authors.lastname: Brocker
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000235:genetics; D001402:B-Lymphocytes / Q000378:metabolism*; D005434:Flow Cytometry; D015870:Gene Expression; D018390:Gene Targeting; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage*; D017919:Hepatitis B Virus, Woodchuck / Q000235:genetics; D006801:Humans; D011401:Promoter Regions, Genetic; D012190:Retroviridae / Q000235:genetics*; D014158:Transcription, Genetic; D019076:Transgenes; D054334:Viral Regulatory and Accessory Proteins; D038301:Virus Inactivation
chemical_list: D018941:Antigens, CD19; D054334:Viral Regulatory and Accessory Proteins